How AI and new research methods are compressing the path from molecule to medicine, and what that means for pharma's decade-long pipelines.
5 articles
Q1 2026 marked a convergence in longevity: $3.74B raised, 173 AI-discovered drugs in trials, the first FDA-approved mitochondrial therapy, and a 71% jump in global events. The sector's bottleneck is no longer discovery; it's whether clinical practice can absorb what's coming.
An AI system designed a drug from scratch that just hit Phase 1 trials. The real story isn't the molecule — it's the swarm of agents that built it.
Innovation often happens at the intersections we least expect, like sports, entertainment, and reproductive biology. Could transforming a live sperm race into a spectator sport unlock new funding streams, spark critical public conversations, and redefine how we engage with health research?
In the rapidly evolving landscape of healthcare and business, a new class of drugs is making waves that extend far beyond the…
The rise of GLP-1 drugs (Ozempic, Mounjaro, Zepbound, etc.) is inadvertently boosting the stock prices of fast food chains. This paradox…
